ArticleFrontiers in public health2022
Time above range for predicting the development of type 2 diabetes.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Carbohydrate composition of infant formula and glycemic regulation in early infancy using continuous glucose monitoring: cross-sectional evidence of altered glucose patterns with corn syrup solid-based formulas.The American journal of clinical nutrition · 2026Observational
- Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia.Diabetes technology & therapeutics · 2026Article
- The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Association of Insulin Resistance and Insulin Secretion Indices and Glucose Metrics From Continuous Glucose Monitoring in People With Obesity.Diabetes care · 2026Article
- Associations of diet composition and quality with continuous glucose monitor-derived glycemic metrics in a community-based cohort.The American journal of clinical nutrition · 2025Article
- Evaluation of Asymptomatic Fasting Hypoglycemia in Outpatients Without Diabetes.Journal of the American Board of Family Medicine : JABFM · 2025Article
- Age, Sex, BMI, Meal Timing, and Glycemic Response to Meal Glycemic Load.JAMA network open · 2025Article
- Improved detection of decreased glucose handling capacities via continuous glucose monitoring-derived indices.Communications medicine · 2025Article
- Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the prognostic value of time range metrics, as measured by continuous glucose monitoring, with respect to the development of type 2 diabetes (T2D). Research design and methods: A total of 499 persons without diabetes from the general population were followed-up for 5 years. Time range metrics were measured at the start and medical records were checked over the period study. Results: Twenty-two subjects (8.3 per 1,000 person-years) developed T2D. After adjusting for age, gender, family history of diabetes, body mass index and glycated hemoglobin concentration, multivariate analysis revealed 'time above range' (TAR, i.e., with a plasma glucose concentration of >140 mg/dL) to be significantly associated with a greater risk (OR = 1.06, CI 1.01-1.11) of developing diabetes (AUC = 0.94, Brier = 0.035). Conclusions: Time above range provides additional information to that offered by glycated hemoglobin to identify patients at a higher risk of developing type 2 diabetes in a population-based study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.